Inhibition of the tissue factor coagulation pathway

Current Vascular Pharmacology

Volumn 2, Issue 4, 2004, Pages 319-327

  Golino, Paolo ^a   Forte, Lavinia ^a   De Rosa, Salvatore ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTITHROMBIN; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A INHIBITOR; DOXYCYCLINE; HEPARIN; HEPARIN DERIVATIVE; MONOCLONAL ANTIBODY; RETROVIRUS VECTOR; TETRACYCLINE; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; ARTERY WALL; BLEEDING TENDENCY; BLOOD VESSEL INJURY; CELL PROLIFERATION; CELL SURFACE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; GENETIC TRANSFECTION; HEMOSTASIS; HUMAN; IN VIVO STUDY; INFLAMMATION; MEDICAL RESEARCH; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; THROMBOGENESIS; THROMBOSIS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; HUMANS; LIPOPROTEINS; THROMBOPLASTIN; THROMBOSIS; TRANSFECTION;

EID: 4444322455     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161043385402     Document Type: Review

References (74)

1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade, initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-10370.
2. Rapaport SI, Rao LV. Initiation and regulation of tissue factor dependent blood coagulation. Aterioscler Thromb 1992; 12: 1111-21.
3. Nemerson Y, Repke D. Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor. Thromb Res 1985; 40: 351-58.
4. Rao LV, Rapaport SI. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988; 85: 6687-91.
5. Radcliffe R, Nemerson V. Activation and control of factor VII by activated factor X and thrombin: Isolation and characterization of a single chain form of factor VII. J Biol Chem 1975; 250: 388-95.
6. Kisiel W, Fujikawa K, Davie EW. Activation of bovine factor VII (proconvertin) by factor XIIa (activated Hageman factor). Biochemistry 1977; 16: 4189-94.
7. Seligsohn U, Osterud B, Brown SF, Griffin JH, Rapaport SI. Activation of human factor VII in plasma and in purified systems: Roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest 1979; 64: 1056.
8. Masys DR, Bajaj SP, Rapaport SI. Activation of human factor VII by activated factors IX and X. Blood 1982; 60: 1143-50.
9. Tsujioka H, Suehiro A, Kakishita E. Activation of coagulation factor VII by tissue-type plasminogen activator. Am J Hematol 1999; 61: 34-9.
10. Nakagaki T, Foster DC, Berkner KL, Kisiel W. Initiation of the extrinsic pathway of blood coagulation: Evidence for the tissue factor dependent autoactivation of human coagulation factor VII. Biochemistry 1991; 30: 10819-24.
11. Neuenschwander PF, Fiore MM, Morrissey JH. Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofacbr complexes. Implications of a two-dimensional enzyme kinetic mechanism. J Biol Chem 1993; 268: 21489-92.
12. Broze GJ Jr, Leykam JE, Schwartz BD, Miletich JP. Purification of human brain tissue factor. J Biol Chem 1985; 260: 10917-20.
13. Paborsky LR, Caras IW, Fisher KL, Gorman CM. Lipid association, but not the trausmembrane domain, is required for tissue factor activity. Substitution of the trausmembrane domain with a phosphatidylinositol anchor. J Biol Chem 1991; 266: 21911-6.
14. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 1991; 266: 2158-66.
15. Drake TA, Morrissey JH, Edington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134(5): 1087-1097.
16. Schecter AD, Giesen P, Taby O, Rosenfield CL, Rossikhina M, Fyfe BS, Kohtz DS, Fallon JT, Nemerson Y, Taubman MB. Tissue factor expression in human arterial smooth muscle cells TF is present in three cellular pools after growth factor stimulation. J Clin Invest 1997; 100; 9: 2276-2285.
17. Pedersen AH, Nordfang O, Norris F, Wl beig FC, Christensen PM, Mueller KB. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem 1990; 265: 16786-93.
18. Payne MA, Neuenschwander PF, Johnson AE, Morrissey JH. Effect of soluble tissue factor on the kinetic mechanism of factor VIIa: Enhancement of p-guanidinobenzoate substrate hydrolysis. Biochemistry 1996; 35: 7100-6.
19. Huang QL, Neuenschwander PF, Rezaie AR, Monrissey JH. Substrate recognition by tissue factor-factor VIta - Evidence for interaction of residues Lys 165 and Lys 166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X. J Biol Chem 1996; 271: 21752-7.
20. Maynard JR, Dreyer BE, Stemerman MB, Pitlick FA. Tissue-factor coagulant activity of cultured human endothelial and smooth muscle cells and fibroblasts. Blood 1977; 50: 387-96.
21. Drake TA, Rut W, Morrissey JH, Edgingtun TS. Functional tissue factor is entirely cell surface expressed on LPS stimulated human blood monocytes and a constitutively tissue factor producing neoplastic cell line. J Cell Biol 1989; 109: 389-95.
22. Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: Regulation by cytosolic calcium. PNAS 1990; 87: 6995-9.
23. Wilcox JN, Smith KM, Schwartz S, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843.
24. Jander S, Sitzer M, Wendt A, Schroeter M, Buchkremer M, Siebler M, Muller W, Sandmann W, Stoll G. Expression of tissue factor in high-grade carotid stenosis: association with plaque destabilization. Stroke 2001; 32: 850-4.
25. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz D, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997; 95: 594-599.
26. Annex BH, Denning SM, Channon KM, Sketch MH, Stack RS, Morrisey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91: 619-622.
27. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349: 769-71 coronary atherosclerotic plaques. Lancet 1997; 349: 769-71
28. Koyama T, Nishida K, Ohdama S, Sawada M, Muratami N, Hirosawa S, Kuriyama R, Matusawa K, Hasegawa R, Aoki N. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 87, 343-347, 1994.
29. Macik BG and Morrissey JH. Determination of activated factor VII (FVIIa) levels in plasma using a clotting assay specific for FVIIa. Blood 1991; 78, 61a (Abstract).
30. Bauer KA, Kass BL, Ten Cate H, Bednarek MA, Hawinger JJ, and Rosenberg, R.D. detection of factor X activation in humans. Blood 74, 2007-2015, 1989.
31. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-2315.
32. Soejima H, Ogawa H, Yasue H, Nishiyama K, Kaikita K, Misumi K, Takazoe K, Kugiama K, Tsuji I, Kumeda K, Nakamura S. Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris. Thromb Res 1999; 93: 17-25.
33. Key NS, Slungaard A, Dandelet L, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-4223.
34. Balasubramanian V, Gabrowski E, Bini A, Nemerson Y. Platelets, circulating Tissue Factor, and fibrine colocalize in ex vivo trombi: real time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood 2002; 100: 2787-2792.
35. Ragni M, Golino P, Cirillo P, Scognamiglio A, Piro O, Esposito N, et al. Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury. Circulation 2000; 102: 113-7.
36. Ravera A, Golino P, Piscione F, Leosco D, Cirillo P, Ragni M, Ezban M, et al. Activation of tissue factor-dependent coagulation pathway in patients with acute myocardial infarction. J Am Coll Cardiol 2000; 35 (Suppl. A): 406.
37. Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99: 2908-2913.
38. 2+ signals in J82 cells, transfected COS-1 cells, Madine-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor. J Biol Chem 1995; 270 (9), 4650-60.
39. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000; 97: 5255-60.
40. Petersen LC, Thastrup O, Hagel G, Sorensen BB, Freskgard PO, Rao LV, Ezban M. Exclusion of known protease activated receptors in factor VIIa-induced signal transduction. Thromb Haemost 2000; 83: 571-6.
41. Camerer E, Rottingen JA, Gjernes E, Larsen K, Skartlien AH, Iversen JG, et al. Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J Biol Chem 1999; 274: 32225-33.
42. Cirillo P, Calabrò P, Calì G, Forte L, De Rosa S, Pacileo M, et al. The binding of the fviia to the tf promotes smooth muscle cell proliferation in vitro via the extracellular signal regulated kinases.european heart journal 23 pag 537, 2002
43. Coughlin SR. Sol Sherry lecture in thrombosis: how thrombin 'talks' to cells: molecular mechanisms and roles in vivo. Arterioseler Thromb Vasc Biol 1998; 18: 514-8.
44. Taniguchi T, Kakkar AK, Tuddenham EGD, Williamson RCN, Leinoine NR. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway ih human pancreatic cancer. Cancer Res 1998; 58: 4461-7.
45. Prydz H. A new paradigm for blood coagulation research. Thromb Haemost 2000; 83: 520-2.
46. Sandset PM and Abildgaard U. The present status of tissue factor pathway inhibitor-The key to feed-back control of blood coagulation initiated by tissue thromboplastin. Haemostasis 21, 219-239,1991.
47. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze J Jr, Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 1993; 4: 661-669
48. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-93.
49. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 1995; 6 Suppl 1: S7-13.
50. Hamik A, Setiadi H, Bo GJ, McEver RP, Morrissey JH. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipuprotein receptor-related protein. J Biol Chem 1999; 274: 4962-9.
51. Sevinsky JR, Rao LVM, Rut W. Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996; 133: 293-304.
52. Ott I, Miyagi Y, Miyazaki K, Heeb MJ, Mueller BM, Rao LVM. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2000; 20: 874-82.
53. Haskel EJ, Torr SR, Day KC, Haskel EJ, Torr SR, Day KC, et al. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991; 84: 821-827.
54. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92: 3041-3050.
55. Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997; 96: 646-652.
56. St. Pierre J, Yang LY, Tamirisa K, Scherrer D, De Ciechi P, Eisenberg P, et al. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs. Arterioscler Thromb Vasc Biol 1999; 19: 2263-2268.
57. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000; 28: 831-3.
58. Golino P, Cirillo P, Calabrò P, Ragni M, D'Andrea D, Chiariello P. Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in inured rabbit carotid arteries. J Am Coll Cardiol 2001; 38: 569-576.
59. Zoldhelyi P, Chen ZQ, Shelat HS, McNatt JM, Willereson JT. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Nat Acad Sci 2000; 98: 4078-4083.
60. Atsuchi N, Nishida T, Marutsuka K, Asada Y, Kamikubo Y, Takeshita A, et al. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries. Circulation 2001; 103(4): 570-5.
61. Pawashe AB, Golino P, Ambrosio G, Migliaccio F, Ragni M, Pascucci I, et al. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res. 1994; 74: 56-63.
62. Ragni M, Cirillo P, Pascucci I, Scognamiglio A, D'Andrea D, Eramo N, et al. A monoclonal antibody against tissue factor shortens tissue-plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation 1996; 93: 1913-1920.
63. Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 1996; 35: 266-72.
64. Kondo S, Kisiel W. Regulation of factor VIIa in plasma: evidence that antithrombin III is the sole plasma protease inhibitor of human factor VIIa. Thromh Res 1987; 46: 325-335.
65. Girard TJ, MacPhail LA, Likert KM, Novutny WF, Miletich JP, Bruze GJ, Jr. Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein. Science 1990; 248: 1421-4.
66. Dennis MS, Lazarus RA. Kunitz domain inhibitors of tissue factor-factor VIIa. II. Potent and specific inhibitors by competitive phage selection. J Biol Chem 1994; 269: 22137-44.
67. Stassen JM, Lambeir A-M, Manhyssens G, Ripka WC, Nystrom A, Sixma JJ. Characterisation of a novel series of aprotinin-derived anticoagulants. In vitro and pharmacological properties. Thromb Haemost 1995; 74: 646-54.
68. Lee A, Agnelli G, Buller H, Ginsberg J, Heit J, Rote W, et al. Dose-response study of recombinant Factor VIIa/Tissue Factor inhibitor recombinant nematode anticoagulant protein c2 in the prevention of postoperative Venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104(1): 74-78.
69. Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithromhotic and anti-lesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996; 26: 76-82.
70. Himber B, Kirebbofer D, Riederer M, Tschopp TB, Steiner B, Roux SP. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 1997; 78: 1142-9.
71. Harker LA. Therapeutic inhibition of thrombin activities, receptors, and production. Hematol Oncol Clin North Am 1998; 12: 1211-30.
72. Golino P, Ragni M, Cirillo P, D' Andrea D, Scognamiglio A, Ravera A, et al. Antithrombotic effects of recombinant human, active site-blocked Factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ Res 1998; 82: 39-46.
73. Golino P, Cirillo P, D'Andrea D, Ragni M, Calabrò P, Ravera M, et al. Long-term antithrombotic effects of human recombinant, active site-blocked factor VIIa in a chronic model of intravascular thrombosis. Circulation 1999; 98: 1727 (Abstract).
74. Rao LVM, Ezban M. Active site-blocked activated factor VII as an effective antithrombotic agent: mechanism of action. Blood Coagul Fibrinolysis 2000; 11: S135-43.